Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Takeda Snares US Approval for Orzeyful in Narcolepsy Type 1
August 7, 2026
-
REGULATORY Nakai Tapped as MHLW’s Top Pharmacy Officer; Ohara to Steer Drug Pricing Reform
August 7, 2026
-
REGULATORY Sarclisa SC, Joenja, Kineret, and 7 More Drugs Bound for NHI Listing
August 6, 2026
-
REGULATORY Chuikyo Clears NHI Listing for Oncolys’ Telomelysin
August 6, 2026
-
BUSINESS AstraZeneca Japan Chief Says MFN Response Requires Drug Pricing Reform
August 5, 2026
-
REGULATORY Outgoing MHLW Pharmacy Chief Eyes AI as Next Frontier for Drug Regulation
August 4, 2026
-
BUSINESS Lilly Blasts Mounjaro Price Cut, Warns over Japan Investment Appeal
August 4, 2026
-
COMMENTARY Signs of Shift in Japan’s Drug Policy, but Cost Pressures Persist
August 3, 2026
-
ORGANIZATION JPMA Chief Seeks Concrete Reforms to Reward Innovation after Honebuto
July 31, 2026
-
BUSINESS Astellas Expands AI Drug Discovery to TPDs, Engineered Proteins
July 30, 2026
-
BUSINESS Some Drug Plants Halt Operations after Kumamoto Temblor, Supplies Unaffected
July 30, 2026
-
BUSINESS Drug Makers, Wholesalers Rush to Gauge Kumamoto Quake Impact
July 29, 2026
-
ORGANIZATION Radiopharma Group Seeks Faster NHI Coverage for PET Imaging Agents
July 28, 2026
-
REGULATORY Japan Panel Green-Lights GSK’s Hep B Drug, Brinsupri, Hyrnuo
July 28, 2026
-
COMMENTARY Rare Cancer Case Raises New Questions about AAV Gene Therapy Safety
July 27, 2026
-
REGULATORY Japan Enacts Revised Immunization Act, Opens Way for RSV Antibodies under NIP
July 27, 2026
-
REGULATORY Japan to Clarify Non-Clinical Data Waivers for Repurposed Drugs, Ease Sakigake Rules
July 24, 2026
-
ORGANIZATION CES Waivers Could Slow Biosimilar Uptake without Better Communication: Industry
July 23, 2026
-
REGULATORY Japan Sees Limited Impact from Planned US Tariffs on Generics
July 23, 2026
-
REGULATORY Ishin Lawmaker Seeks Full Chuikyo Seat for Industry, but with Fiscal Responsibility
July 22, 2026
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…